Comparative Pharmacology
Head-to-head clinical analysis: VIZZ versus WEZLANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIZZ versus WEZLANA.
VIZZ vs WEZLANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
80 mg orally once daily
IV: 500 mg every 12 hours over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours. Steady-state is reached within 4-5 days; accumulation may occur in renal impairment.
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Primarily hepatic metabolism with renal excretion of metabolites. Approximately 60% of a dose is excreted in urine as metabolites, 30% in feces, and <5% unchanged.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Category C
Category C
Unknown
Unknown